1 |
Chung JW. Recent advance in international management of hepatocellular carcinoma. J Korean Med Assoc. 2013;56:972-982
DOI
|
2 |
Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008; 38:358-366
DOI
|
3 |
Boyle DA. Hepatocellular carcinoma: implications for asia-pacific oncology nurses. Asia Pac J Oncol Nurs. 2017;4:98-103
DOI
|
4 |
통계청. 2017 사망원인통계. 온라인 간행물; 2018. p.1-55
|
5 |
보건복지부, 신의료기술평가위원회. 동맥경유 방사선색전술의 신의료기술평가보고서. 온라인 간행물; 2010. p.1-180
|
6 |
Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018
DOI
|
7 |
Korean Liver Cancer Study Group. 2014 Korean liver cancer study group-national cancer center korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol. 2015; 16:465-522
DOI
|
8 |
대한간암학회, 국립암센터. 2018 간세포암종 진료 가이드라인. 온라인 간행물; 2018. p.1-169
|
9 |
Bouvry C, Palard X, Edeline J, Ardisson V, Loyer P, Garin E, et al. Transarterial Radioembolization (TARE) Agents beyond -Microspheres. Biomed Res Int. 2018; 2018:1435302
DOI
|